GOLMAITA
Live / Allowed — Notice of allowance issued (as of 20 Jan 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 26 Aug 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98716503
- Mark type
- Stylized text
- Filed
- 26 Aug 2024
- Published for opposition
- 25 Nov 2025
- Attorney of record
- Marilyn F. Kelly
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis
Owner
- Celgene Corporation, Princeton, NJ, US
- Celgene Corporation, Princeton, NJ, US
Prosecution history
- 20 Jan 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 25 Nov 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Nov 2025 — PUBLISHED FOR OPPOSITION
- 19 Nov 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 27 Oct 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 27 Oct 2025 — EXAMINER'S AMENDMENT ENTERED
- 27 Oct 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 27 Oct 2025 — EXAMINERS AMENDMENT E-MAILED
- 27 Oct 2025 — EXAMINERS AMENDMENT -WRITTEN
- 12 Jul 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 12 Jul 2025 — FINAL REFUSAL E-MAILED
- 12 Jul 2025 — FINAL REFUSAL WRITTEN
- 09 Jun 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 09 Jun 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 09 Jun 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED